Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) Stock Has Consensus Price Target of $8.33

Shares of Whitehawk Therapeutics, Inc. (NASDAQ:WHWK) have been assigned an average recommendation of “Moderate Buy” from the eight ratings firms that are covering the company, Marketbeat reports. One equities research analyst has rated the stock with a sell rating and seven have assigned a buy rating to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $8.33.

A number of equities analysts have recently commented on WHWK shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Whitehawk Therapeutics in a report on Wednesday, September 2nd. Leerink Partners initiated coverage on shares of Whitehawk Therapeutics in a report on Monday, July 13th. They issued an “outperform” rating and a $9.00 target price for the company. Wall Street Zen upgraded shares of Whitehawk Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 8th. B. Riley Financial began coverage on shares of Whitehawk Therapeutics in a research report on Thursday, June 25th. They set a “buy” rating and a $10.00 price objective for the company. Finally, Stifel Nicolaus assumed coverage on shares of Whitehawk Therapeutics in a research note on Wednesday, September 30th. They issued a “buy” rating and a $9.00 price objective for the company.

Institutional Investors Weigh In On Whitehawk Therapeutics

Several hedge funds have recently modified their holdings of WHWK. Two Sigma Securities LLC bought a new stake in Whitehawk Therapeutics during the 2nd quarter worth $46,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Whitehawk Therapeutics during the first quarter valued at about $40,000. Deutsche Bank AG bought a new stake in shares of Whitehawk Therapeutics during the second quarter worth about $145,000. Bank of America Corp DE acquired a new position in shares of Whitehawk Therapeutics in the second quarter valued at approximately $159,000. Finally, Seven Fleet Capital Management LP bought a new position in Whitehawk Therapeutics in the 1st quarter valued at approximately $187,000. Institutional investors and hedge funds own 52.08% of the company’s stock.

Whitehawk Therapeutics Price Performance

Shares of NASDAQ:WHWK opened at $3.52 on Thursday. The company’s 50 day simple moving average is $4.27 and its 200 day simple moving average is $4.13. The stock has a market capitalization of $200.68 million, a price-to-earnings ratio of -3.14 and a beta of 0.92. Whitehawk Therapeutics has a 1 year low of $1.87 and a 1 year high of $5.49.

Whitehawk Therapeutics (NASDAQ:WHWK) last released its earnings results on Thursday, August 6th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.30) by $0.10. As a group, analysts anticipate that Whitehawk Therapeutics will post -1.07 EPS for the current fiscal year.

About Whitehawk Therapeutics

Whitehawk Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and other serious diseases. The company’s work centers on precision medicines intended to selectively target diseased cells while limiting damage to healthy tissue.

Whitehawk Therapeutics is advancing a pipeline of investigational therapeutic programs, with development activities focused primarily on oncology. As a clinical-stage company, its product candidates remain subject to preclinical and clinical testing, as well as review by applicable regulatory authorities, before any potential commercialization.

Publicly available information about the company’s specific pipeline, geographic operations, and leadership is limited.